In the presence of systemic illness and/or sepsis, initiation of empirical intravenous antibacterial therapy always covering Staphylococcus, Pseudomonas and Enterobacteriaceae species, also taking local institutional epidemiology and colonization (e.g. methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci) into consideration, is recommended.  I  C